Our Clinical Trials
We announced first clinical results with lead program AX-158 in early 2025. Please join our research mission to improve treatments for autoimmune disease through the potential use of Nck modulators.
Clinical trials FAQ
- What trials are currently ongoing with AX-158?
- What do I do if I would like to participate in a clinical trial sponsored by Artax Biopharma?
What trials are currently ongoing with AX-158?
AX-158 was evaluated in a Phase 2a trial in people with mild to moderate plaque psoriasis in multiple centers in the UK. Participants were randomized 2:1 to receive a single daily dose of 10mg AX-158 or placebo. A total of 30 participants were treated for 28 days and followed for an additional 30 days for safety. The main objectives of the study were safety and proof of mechanism. Please click here for more information.
The Phase 2a study confirmed the well-tolerated safety profile seen in the Phase 1 studies, with no infections reported and no severe adverse events. The few adverse events reported were mild or moderate in nature and resolved without intervention, and there were no trial discontinuations.
An extensive psoriasis biomarker analysis was designed, conducted, and analyzed by Dr. James Krueger, Head of Laboratory for Investigative Dermatology at the Rockefeller University and member of the Scientific Advisory Board at Artax Biopharma. His analysis demonstrates statistically significant and consistent effects on both disease and pathway-related genes in participants treated with AX-158.
The company intends to report the results at an upcoming medical conference.
What do I do if I would like to participate in a clinical trial sponsored by Artax Biopharma?
Please ask your physician if you qualify to participate in one of our clinical trials.